Skip to content
Information Technology, Medical Health Aged Care

AI-powered endoscopes to help reduce cancer screening times

Monash University 2 mins read

Artificial intelligence will soon help doctors detect cancerous lesions in real-time during endoscopic procedures, through a new collaboration between medical device company Optiscan Imaging Ltd (Optiscan) and Monash University’s digital health experts. 

 

Announced today, an agreement between Monash University’s Faculty of Information Technology and Optiscan will advance a project to develop a next generation gastrointestinal (GI) flexible endomicroscope enabled with edge-artificial intelligence (AI) technology. 

 

Leader of the project’s AI research component, Associate Professor Zongyuan Ge and Dr. Yasmeen George from the AIM for Health Lab at the Faculty’s Department of Data Science and AI, said the goal was to develop an AI analysis platform with a miniature digital microscope from Optiscan that can fit biopsy channels of most endoscopes and provide real-time images at a subcellular level.

 

“The system will be powered by an AI engine to automatically detect and analyse abnormal cells,” Associate Professor Ge said. 

 

“It will allow clinicians to conduct real-time GI endomicroscopy examinations and initiate immediate medical intervention if abnormalities are detected, which will significantly reduce cancer screening times, increase the chances of successful treatment and improve the prognosis of patients.”

 

Faculty of Information Technology Dean Professor Ann Nicholson welcomed the partnership and the opportunity to translate the Faculty’s leading AI research to produce tangible outcomes. 

 

"Uniting advanced AI with industry capabilities in this way is inspiring. It is a demonstration of how industrial innovation can join hands with research expertise to drive meaningful, practical improvements in patient health and reshape the future of cancer detection,” Professor Nicholson said. 

 

The project is supported by the Cooperative Research Centres Projects (CRC-P) grant from the Australian Department of Industry, Science, and Resources, awarded to Optiscan. 

 

Optiscan CEO and Managing Director Dr Camile Farah said the company was thrilled to partner with Monash University for the next development phase of their innovative GI endomicroscope. 

 

“This agreement between us and Monash University represents a significant step towards better diagnosis and treatment of gastrointestinal diseases,” Dr Farah said. 

 

“It also represents another chapter in the longstanding relationship Optiscan has with Monash University, with our technology originally created at this prestigious university.”

 

Monash University’s digital health researchers will join Optiscan’s existing partners Design & Industry and the University Medical Center Mainz in Germany to progress this project. 

 

Associate Professor Zongyuan Ge from the Faculty of Information Technology’s Department of Data Science and AI is available for interviews. 

 

MEDIA ENQUIRIES

Teju Hari Krishna, Monash University

T: +61 450 501 248 E: [email protected]

For more Monash media stories, visit our news and events site. 

More from this category

  • Medical Health Aged Care
  • 28/01/2026
  • 06:00
Monash University

Monash study shows subcutaneous delivery with hyaluronidase may boost effectiveness of cancer immunotherapy

Monash University researchers alongside key partner Halozyme Therapeutics have reported findings in support of shifting the way anti-cancer immunotherapy is administered from intravenous administration to subcutaneous administration in combination with recombinant hyaluronidase. This approach makes it less complex and painful for the patient, and may improve the treatment outcome for some medicines. The study published in Cancer Immunology Research, addresses a current challenge that is that monoclonal antibody (mAb) immunotherapies typically require high doses/volumes to be effective and as a result are infused intravenously. In contrast, subcutaneous administration, where an injection is given under the skin, is an increasingly patient-preferred…

  • Information Technology
  • 28/01/2026
  • 01:40
Acoustic, L.P.

Acoustic Launches Native Integrations with Leading Commerce Platforms

Enterprise-Grade Connections to BigCommerce, Shopify, and WooCommerce Deliver Real-Time Catalog Sync and Unified Customer Insights for Retail MarketersBOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Acoustic, a global leader in omnichannel marketing technology and customer engagement, today announced the availability of native, bi-directional integrations with the industry’s leading commerce platforms — Shopify, WooCommerce, and BigCommerce — inside its flagship platform, Acoustic Connect™.The new integrations provide real-time, enterprise-scale ingestion of product catalogs, customer profiles, order events, and behavioral signals, giving ecommerce and retail marketers a comprehensive, continuously updated view of every customer interaction. This enhanced visibility allows marketers to see the moment…

  • Information Technology
  • 28/01/2026
  • 00:26
Symetrix

Symetrix Unveils Cognio: The Next-Generation Audio, Video, and Control Platform

With breakthrough distributed architecture and wire-free design workflows, Cognio redefines how AV systems are designed, deployed, and operated; see it for the first time…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.